Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-001
- Development stage
- Phase 2
- Lead developer
- Shanghai Chaoyang Pharmaceutical
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
HP-001 is a degradable molecular glue drug candidate developed by Shanghai Helioson Pharmaceutical. It functions as an inhibitor of the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), which are zinc finger proteins involved in the regulation of lymphocyte development and survival. By promoting the degradation of these proteins, HP-001 is designed to disrupt cancer cell growth, particularly in hematologic malignancies such as multiple myeloma and non-Hodgkin's lymphoma. The drug is currently being evaluated in Phase 1 clinical trials for relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma[1][4].
02
Targets
IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on HP-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-001.